Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cem Akin

Showing results (151-160 of 203) with videos related to

Pageof 21
Sort By:
The Journal of Allergy and Clinical Immunology|April 14, 2022
Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?Peter Valent, Cem Akin, Karin Hartmann, et al.
The Journal of Allergy and Clinical Immunology. Global|September 12, 2022
Vaccination counseling with and without excipient skin testing in patients with suspected allergic reactions to mRNA COVID-19 vaccines and patients with atopyDilawar Khokhar, Kelly M O'Shea, Cem Akin, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2007
KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entitiesIrina Maric, Jamie Robyn, Dean D Metcalfe, et al.
Current Allergy and Asthma Reports|February 17, 2026
Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil ActivationPeter Valent, Karin Hartmann, Gabriele Stefanzl, et al.
The Journal of Allergy and Clinical Immunology|April 17, 2022
Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022Michel Arock, Gregor Hoermann, Karl Sotlar, et al.
Haematologica|October 4, 2016
Advanced systemic mastocytosis: from molecular and genetic progress to clinical practiceCelalettin Ustun, Michel Arock, Hanneke C Kluin-Nelemans, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 25, 2021
COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptomsMatthew P Giannetti, Emily Weller, Iván Alvarez-Twose, et al.
The Journal of Allergy and Clinical Immunology|May 22, 2020
Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosisKarin Hartmann, Jason Gotlib, Cem Akin, et al.
The Journal of Allergy and Clinical Immunology|September 3, 2019
AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and managementCatherine R Weiler, K Frank Austen, Cem Akin, et al.
The World Allergy Organization Journal|March 23, 2026
Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosisThanai Pongdee, Mariana Castells, Cem Akin, et al.
Pageof 21

Showing results (151-160 of 203) with videos related to

Sort By:
Pageof 21
The Journal of Allergy and Clinical Immunology|April 14, 2022
Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?Peter Valent, Cem Akin, Karin Hartmann, et al.
The Journal of Allergy and Clinical Immunology. Global|September 12, 2022
Vaccination counseling with and without excipient skin testing in patients with suspected allergic reactions to mRNA COVID-19 vaccines and patients with atopyDilawar Khokhar, Kelly M O'Shea, Cem Akin, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2007
KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entitiesIrina Maric, Jamie Robyn, Dean D Metcalfe, et al.
Current Allergy and Asthma Reports|February 17, 2026
Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil ActivationPeter Valent, Karin Hartmann, Gabriele Stefanzl, et al.
The Journal of Allergy and Clinical Immunology|April 17, 2022
Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022Michel Arock, Gregor Hoermann, Karl Sotlar, et al.
Haematologica|October 4, 2016
Advanced systemic mastocytosis: from molecular and genetic progress to clinical practiceCelalettin Ustun, Michel Arock, Hanneke C Kluin-Nelemans, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 25, 2021
COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptomsMatthew P Giannetti, Emily Weller, Iván Alvarez-Twose, et al.
The Journal of Allergy and Clinical Immunology|May 22, 2020
Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosisKarin Hartmann, Jason Gotlib, Cem Akin, et al.
The Journal of Allergy and Clinical Immunology|September 3, 2019
AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and managementCatherine R Weiler, K Frank Austen, Cem Akin, et al.
The World Allergy Organization Journal|March 23, 2026
Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosisThanai Pongdee, Mariana Castells, Cem Akin, et al.
Pageof 21